Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

SUM159 cells treated with H3B-8800 or DMSO, Cytoplasmic fraction RNA-seq

ABSTRACT: The objective is to identify splicing changes that occur after spliceosome inhibition in triple-negative breast cancer, specifically in cytoplasmic RNA.

ORGANISM(S): Homo sapiens

PROVIDER: GSE163232 | GEO | 2020/12/17

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

SUM159 cells treated with H3B-8800 or DMSO, J2 enrichment for dsRNA

Project description:The objective is to identify splicing and expression changes that occur after spliceosome inhibition in triple-negative breast cancer, specifically after the RNA has been enriched for double-stranded structure using the J2 antibody.

2020-12-17 | GSE163188 | GEO

SUM159 cells treated with H3B-8800 or DMSO, Cytoplasmic fraction RNA-seq

Project description:SUM159 cells treated with H3B-8800 or DMSO, Cytoplasmic fraction RNA-seq

| PRJNA685408 | ENA

T11, AT3, PyMT-M, 2208L GEMM tumors treated with H3B-8800

Project description:The objective is to identify splicing and expression changes that occur after spliceosome inhibition in triple-negative breast cancer using immune competent GEMM tumors.

2020-12-17 | GSE163181 | GEO

SUM159 cells treated with sudemycin D6 (SD6)

Project description:The objective is to identify gene expression patterns that occur after spliceosome inhibition in triple-negative breast cancer.

2020-12-18 | GSE163414 | GEO

H3B-8800, a novel oral splicing modulator, induces lethality in spliceosome mutant cancers [K562]

Project description:Genomic analyses of cancer have identified recurrent point mutations in the RNA splicing factors SF3B1, U2AF1, and SRSF2 that confer an alteration of function. Although cells bearing these mutations are preferentially dependent on wild-type (WT) spliceosome function, clinical means to therapeutically target the spliceosome do not currently exist. Here, we describe an orally available modulator of the SF3b complex, H3B-8800, which potently and selectively kills spliceosome-mutant epithelial and hematologic malignancies. The effects of H3B-8800 are entirely selective for the Sf3b complex, as evidenced by the identification of drug-resistant cells bearing mutations in Sf3b components. Although H3B-8800 modulates RNA splicing mediated by WT or cancer-associated SF3B1 mutants, its preferential effects on spliceosome-mutant cells is due to preferred retention of short, GC-rich introns, which are enriched in genes encoding a substantial number of spliceosome components. These data demonstrate the therapeutic potential of splicing modulation in spliceosome-mutant cancers.

2017-12-20 | GSE94528 | GEO

H3B-8800, a novel oral splicing modulator, induces lethality in spliceosome mutant cancers [Nalm-6]

2017-12-20 | GSE94999 | GEO

H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.

Project description: Not available

| S-EPMC6730556 | biostudies-literature

SUM159 cells treated with H3B-8800 or DMSO, J2 enrichment for dsRNA

Project description:SUM159 cells treated with H3B-8800 or DMSO, J2 enrichment for dsRNA

| PRJNA685161 | ENA

MDA-MB-231-LM2 cells treated with sudemycin D6 (SD6)

Project description:The objective is to identify gene expression patterns that occur after spliceosome inhibition in triple-negative breast cancer.

2020-12-18 | GSE163411 | GEO

Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms.

Project description: Not available

| S-EPMC8632688 | biostudies-literature